{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:22:14Z","timestamp":1783045334632,"version":"3.54.6"},"reference-count":205,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1690,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Polish National Agency for Academic Exchange","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The most common cancer diagnosis in female population is breast cancer, which affects every year about 2.0 million women worldwide. In recent years, significant progress has been made in oncological therapy, in systemic treatment, and in radiotherapy of breast cancer. Unfortunately, the improvement in the effectiveness of oncological treatment and prolonging patients' life span is associated with more frequent occurrence of organ complications, which are side effects of this treatment. Current recommendations suggest a periodic monitoring of the cardiovascular system in course of oncological treatment. The monitoring includes the assessment of occurrence of risk factors for cardiovascular diseases in combination with the evaluation of the left ventricular systolic function using echocardiography and electrocardiography as well as with the analysis of the concentration of cardiac biomarkers. The aim of this review was critical assessment of the breast cancer therapy cardiotoxicity and the analysis of methods its detections. The new cardio-specific biomarkers in serum, the development of modern imaging techniques (Global Longitudinal Strain and Three-Dimensional Left Ventricular Ejection Fraction) and genotyping, and especially their combined use, may become a useful tool for identifying patients at risk of developing cardiotoxicity, who require further cardiovascular monitoring or cardioprotective therapy.<\/jats:p>","DOI":"10.1002\/ehf2.13365","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T13:04:08Z","timestamp":1620306248000},"page":"2397-2418","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Adjuvant Breast Cancer Treatments Cardiotoxicity and Modern Methods of Detection and Prevention of Cardiac Complications"],"prefix":"10.1093","volume":"8","author":[{"given":"Agata","family":"Bikiewicz","sequence":"first","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI) , Rzgowska 281\/289, Lodz, 93-338 ,","place":["Poland"]},{"name":"Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz , Lodz ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI) , Rzgowska 281\/289, Lodz, 93-338 ,","place":["Poland"]},{"name":"Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz , Lodz ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology and German Center for Cardiovascular Research (DZHK), partner site G\u00f6ttingen, University Medical Center G\u00f6ttingen (UMG) , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI) , Lodz ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Bielecka-Dabrowa","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI) , Rzgowska 281\/289, Lodz, 93-338 ,","place":["Poland"]},{"name":"Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz , Lodz ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"2026012114205980000_ehf213365-bib-0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2026012114205980000_ehf213365-bib-0002","first-page":"151","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2026012114205980000_ehf213365-bib-0003","first-page":"184","article-title":"Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"69","author":"Smith","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2026012114205980000_ehf213365-bib-0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7326\/M19-2125","article-title":"European Commission Initiative on Breast Cancer (ECIBC) Contributor Group. Breast cancer screening and diagnosis: a synopsis of the European breast guidelines","volume":"172","author":"Sch\u00fcnemann","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026012114205980000_ehf213365-bib-0005","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"key":"2026012114205980000_ehf213365-bib-0006","first-page":"181","article-title":"WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the breast","volume":"77","author":"Hoon Tan","year":"2020","journal-title":"Histopathology"},{"key":"2026012114205980000_ehf213365-bib-0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"2026012114205980000_ehf213365-bib-0008","doi-asserted-by":"crossref","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN guidelines insights: breast cancer, version 1.2017","volume":"15","author":"Gradishar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2026012114205980000_ehf213365-bib-0009","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2026012114205980000_ehf213365-bib-0010","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0011","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114205980000_ehf213365-bib-0012","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"2026012114205980000_ehf213365-bib-0013","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-80-2-249","article-title":"Adriamycin. A new anticancer drug with significant clinical activity","volume":"80","author":"Blum","year":"1974","journal-title":"Ann Intern Med"},{"key":"2026012114205980000_ehf213365-bib-0014","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"2026012114205980000_ehf213365-bib-0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15420\/cfr.2018.32.2","article-title":"Heart failure and cancer: mechanisms of old and new cardiotoxic drugs in cancer patients","volume":"5","author":"Cuomo","year":"2019","journal-title":"Card Fail Rev"},{"key":"2026012114205980000_ehf213365-bib-0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40169-017-0148-3","article-title":"Anthracycline induced cardiotoxicity: biomarkers and \u201cOmics\u201d technology in the era of patient specific care","volume":"6","author":"Moazeni","year":"2017","journal-title":"Clin Transl Med"},{"key":"2026012114205980000_ehf213365-bib-0017","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1093\/nar\/gkn774","article-title":"Interaction of anthracyclines with iron responsive element mRNAs","volume":"36","author":"Canzoneri","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"2026012114205980000_ehf213365-bib-0018","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fphar.2018.01262","article-title":"Updates in anthracycline-mediated cardiotoxicity","volume":"9","author":"Nebigil","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026012114205980000_ehf213365-bib-0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.110.950543","article-title":"Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase \u03b3 activity in pressure overload-induced cardiac failure","volume":"123","author":"Damilano","year":"2011","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2004.07.017","article-title":"PI3K\u03b3 modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects","volume":"118","author":"Patrucco","year":"2004","journal-title":"Cell"},{"key":"2026012114205980000_ehf213365-bib-0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/01.CIR.104.3.330","article-title":"Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo","volume":"104","author":"Matsui","year":"2001","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0022","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.yjmcc.2003.09.012","article-title":"Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase\/Akt","volume":"35","author":"Fukazawa","year":"2003","journal-title":"J Mol Cell Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0023","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The: Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114205980000_ehf213365-bib-0024","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2026012114205980000_ehf213365-bib-0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0026","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0027","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"2026012114205980000_ehf213365-bib-0028","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"2026012114205980000_ehf213365-bib-0029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1940-6207.CAPR-11-0334","article-title":"Targeting the HER\/EGFR\/ErbB family to prevent breast cancer","volume":"4","author":"Howe","year":"2011","journal-title":"Cancer Prev Res"},{"key":"2026012114205980000_ehf213365-bib-0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur J Cancer"},{"key":"2026012114205980000_ehf213365-bib-0032","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2; its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"2026012114205980000_ehf213365-bib-0033","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"issue":"10","key":"2026012114205980000_ehf213365-bib-0034","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1161\/CIRCRESAHA.112.267286","article-title":"Neuregulin in cardiovascular development and disease","volume":"111","author":"Odiete","year":"2012","journal-title":"Circulation Research"},{"key":"2026012114205980000_ehf213365-bib-0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"2026012114205980000_ehf213365-bib-0036","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"2026012114205980000_ehf213365-bib-0037","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0038","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012114205980000_ehf213365-bib-0039","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0040","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/annonc\/mdq096","article-title":"Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer","volume":"21","author":"Costa","year":"2010","journal-title":"Ann Oncol"},{"key":"2026012114205980000_ehf213365-bib-0041","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2026012114205980000_ehf213365-bib-0042","volume-title":"Commissioner announces Avastin decision\u2014drug not shown to be safe and effective in breast cancer patients","author":"Food and Drug Association (FDA)","year":"2011"},{"key":"2026012114205980000_ehf213365-bib-0043","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"2026012114205980000_ehf213365-bib-0044","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1185\/03007995.2012.707643","article-title":"Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC)","volume":"28","author":"Riemsma","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2026012114205980000_ehf213365-bib-0045","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.clinthera.2009.11.029","article-title":"Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer","volume":"31","author":"Tevaarwerk","year":"2009","journal-title":"Clin Ther"},{"key":"2026012114205980000_ehf213365-bib-0046","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10549-017-4460-9","article-title":"Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis","volume":"166","author":"Choi","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2026012114205980000_ehf213365-bib-0047","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2005.12.157","article-title":"Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies","volume":"23","author":"Spector","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0048","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2026012114205980000_ehf213365-bib-0049","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2026012114205980000_ehf213365-bib-0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"key":"2026012114205980000_ehf213365-bib-0051","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0140-6736(76)90151-3","article-title":"Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity","volume":"1","author":"Appelbaum","year":"1976","journal-title":"Lancet"},{"key":"2026012114205980000_ehf213365-bib-0052","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jjcc.2009.01.006","article-title":"Fulminant fatal cardiotoxicity following cyclophosphamide therapy","volume":"54","author":"Katayama","year":"2009","journal-title":"J Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0053","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2169\/internalmedicine.44.120","article-title":"Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation","volume":"44","author":"Kamezaki","year":"2005","journal-title":"Intern Med"},{"key":"2026012114205980000_ehf213365-bib-0054","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(00)02051-1","article-title":"QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide","volume":"355","author":"Nakamae","year":"2000","journal-title":"Lancet"},{"key":"2026012114205980000_ehf213365-bib-0055","first-page":"400","article-title":"Marrow transplanation in man following cyclophosphamide","volume":"3","author":"Santos","year":"1971","journal-title":"Transplant Proc"},{"key":"2026012114205980000_ehf213365-bib-0056","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood"},{"key":"2026012114205980000_ehf213365-bib-0057","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/sj.bmt.1702234","article-title":"Cardiac and pulmonary toxicity in patients undergoing high-dose chemo-therapy for lymphoma and breast cancer: prognostic factors","volume":"25","author":"Brockstein","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2026012114205980000_ehf213365-bib-0058","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/bi00700a012","article-title":"Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate","volume":"13","author":"Santi","year":"1974","journal-title":"Biochemistry"},{"key":"2026012114205980000_ehf213365-bib-0059","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0006-291X(74)90601-9","article-title":"Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2\u2032-deoxyuridylate and methylenetetrahydrofolate","volume":"57","author":"Sommer","year":"1974","journal-title":"Biochem Biophys Res Commun"},{"key":"2026012114205980000_ehf213365-bib-0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/00001813-200109000-00001","article-title":"Capecitabine: a novel agent for the treatment of solid tumors","volume":"12","author":"Johnston","year":"2001","journal-title":"Anticancer Drugs"},{"key":"2026012114205980000_ehf213365-bib-0061","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568011023354146","article-title":"The prodrugs of 5-fluorouracil","volume":"2","author":"Malet-Martino","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"2026012114205980000_ehf213365-bib-0062","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"4","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026012114205980000_ehf213365-bib-0063","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"2026012114205980000_ehf213365-bib-0064","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026012114205980000_ehf213365-bib-0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/MBC.0b013e3283597605","article-title":"Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction","volume":"24","author":"Ozturk","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2026012114205980000_ehf213365-bib-0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytz146","article-title":"Fluorouracil-induced Takotsubo cardiomyopathy causing cardiogenic shock: a case report of clinical and acute cardiac magnetic resonance imaging features","volume":"3","author":"Joy","year":"2019","journal-title":"Eur Heart J Case Rep"},{"key":"2026012114205980000_ehf213365-bib-0067","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions","volume":"14","author":"Chong","year":"2019","journal-title":"Interv Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0068","first-page":"320","article-title":"Capecitabine may induce coronary artery vasospasm","volume":"53","author":"Tsiamis","year":"2012","journal-title":"Hellenic J Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0069","first-page":"183","article-title":"Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil","volume":"20","author":"Moriyama","year":"2019","journal-title":"J Cases"},{"key":"2026012114205980000_ehf213365-bib-0070","first-page":"26","article-title":"A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: A case report","volume":"16","author":"Hayasaka","year":"2017","journal-title":"J Cardiol Cases"},{"key":"2026012114205980000_ehf213365-bib-0071","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0973-1482.37412","article-title":"Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil","volume":"3","author":"Talapatra","year":"2007","journal-title":"J Cancer Res Ther"},{"key":"2026012114205980000_ehf213365-bib-0072","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ajem.2010.10.025","article-title":"Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis","volume":"30","author":"Calik","year":"2012","journal-title":"Am J Emerg Med"},{"key":"2026012114205980000_ehf213365-bib-0073","article-title":"5-fluorouracil induced pericarditis","volume":"15","author":"Killu","year":"2011","journal-title":"BMJ Case Rep"},{"key":"2026012114205980000_ehf213365-bib-0074","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209347","article-title":"5-Fluorouracil cardiotoxicity: reversible left ventricular systolic dysfunction with early detection","volume":"2015","author":"Iskandar","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2026012114205980000_ehf213365-bib-0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.COC.0000017526.55135.6D","article-title":"Severe toxicity related to the 5-fluorouracil\/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients","volume":"26","author":"Tsalic","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0076","first-page":"I51","article-title":"Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy\u2014a survey of 427 patients","volume":"8","author":"Tsavaris","year":"2002","journal-title":"Med Sci Monit"},{"key":"2026012114205980000_ehf213365-bib-0077","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"key":"2026012114205980000_ehf213365-bib-0078","first-page":"23","article-title":"Taxanes in adjuvant and neoadjuvant therapies for breast cancer","volume":"12","author":"O'Leary","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"2026012114205980000_ehf213365-bib-0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543776.2016.1111872","article-title":"Taxane anticancer agents: a patent perspective","volume":"26","author":"Ojima","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"2026012114205980000_ehf213365-bib-0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2026012114205980000_ehf213365-bib-0081","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/14728222.2013.733001","article-title":"Targeting the Bcl-2 family for cancer therapy","volume":"17","author":"Thomas","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"2026012114205980000_ehf213365-bib-0082","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/14740338.2.1.59","article-title":"Cardiotoxic effects of anthracycline-taxane combinations","volume":"2","author":"Perotti","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"2026012114205980000_ehf213365-bib-0083","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.106.103846","article-title":"Paclitaxel and docetaxel stimulation of doxo-rubicinol formation in the human heart: implications for cardio-toxicity of doxorubicin-taxane chemotherapies","volume":"318","author":"Salvatorelli","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012114205980000_ehf213365-bib-0084","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (Taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","article-title":"Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes","volume":"7","author":"Gianni","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"2026012114205980000_ehf213365-bib-0086","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/annonc\/mdt584","article-title":"BRENDA study group. The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects","volume":"25","author":"W\u00f6ckel","year":"2014","journal-title":"Ann Oncol"},{"key":"2026012114205980000_ehf213365-bib-0087","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0088","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol"},{"key":"2026012114205980000_ehf213365-bib-0089","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ijrobp.2007.05.034","article-title":"Cardiac exposures in breast cancer radiotherapy: 1950s-1990s","volume":"69","author":"Taylor","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026012114205980000_ehf213365-bib-0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejcsup.2014.03.002","article-title":"Cardiovascular disease after cancer therapy","volume":"12","author":"Aleman","year":"2014","journal-title":"EJC Suppl"},{"key":"2026012114205980000_ehf213365-bib-0091","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1089\/ars.2012.5000","article-title":"Redox-modulated phenomena and radiation therapy: the central role of superoxide dismutases","volume":"20","author":"Holley","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"2026012114205980000_ehf213365-bib-0092","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5114\/jcb.2014.47891","article-title":"Comparison of radiation dose to the left anterior descending artery by whole and partial breast irradiation in breast cancer patients","volume":"7","author":"Sato","year":"2015","journal-title":"J Contemp Brachytherapy"},{"key":"2026012114205980000_ehf213365-bib-0093","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.11.016","article-title":"Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration","volume":"73","author":"Demirci","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026012114205980000_ehf213365-bib-0094","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/heartjnl-2015-308765","article-title":"Radiation-induced valvular heart disease","volume":"102","author":"Gujral","year":"2016","journal-title":"Heart"},{"key":"2026012114205980000_ehf213365-bib-0095","first-page":"681","article-title":"Radiation-associated valvular heart disease in Hodgkin's disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain","volume":"10","author":"Brand","year":"2001","journal-title":"J Heart Valve Dis"},{"key":"2026012114205980000_ehf213365-bib-0096","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.amjcard.2015.11.027","article-title":"Assessment of valvular disorders in survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy\u2009\u00b1\u2009chemotherapy","volume":"117","author":"Bijl","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0097","first-page":"583","article-title":"Pathogenesis and prevention of radiation-induced myocardial fibrosis","volume":"18","author":"Liu","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026012114205980000_ehf213365-bib-0098","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026012114205980000_ehf213365-bib-0099","first-page":"785","article-title":"Recent advances in radiation oncology","volume":"11","author":"Garibaldi","year":"2017","journal-title":"Ecance Mmed Sci"},{"key":"2026012114205980000_ehf213365-bib-0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jrr\/rrw064","article-title":"Pathology and biology of radiation-induced cardiac disease","volume":"57","author":"Tapio","year":"2016","journal-title":"J Radiat Res"},{"key":"2026012114205980000_ehf213365-bib-0101","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0046-8177(96)90447-5","article-title":"Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases","volume":"27","author":"Veinot","year":"1996","journal-title":"Hum Pathol"},{"key":"2026012114205980000_ehf213365-bib-0102","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jrr\/rry029","article-title":"Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer\u2014comparison of four-field technique and traditional two opposed fields technique","volume":"59","author":"Takata","year":"2018","journal-title":"J Radiat Res"},{"key":"2026012114205980000_ehf213365-bib-0103","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1200\/JCO.2004.09.109","article-title":"Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy","volume":"22","author":"Adams","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.clon.2004.09.016","article-title":"Cardiac complications of radiation therapy","volume":"17","author":"Gaya","year":"2005","journal-title":"Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0105","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1200\/JCO.2008.17.3203","article-title":"Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer","volume":"26","author":"Coccaro","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0106","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.1993.11.7.1208","article-title":"Cardiac disease following treatment of Hodgkin's disease in children and adolescents","volume":"11","author":"Hancock","year":"1993","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0107","first-page":"2487","article-title":"Radiation-associated cardiac injury","volume":"35","author":"Eldabaje","year":"2015","journal-title":"Anticancer Res"},{"key":"2026012114205980000_ehf213365-bib-0108","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.seminoncol.2013.01.005","article-title":"Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance","volume":"40","author":"Carver","year":"2013","journal-title":"Semin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0109","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/14656566.8.8.1039","article-title":"Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management","volume":"8","author":"Barry","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"2026012114205980000_ehf213365-bib-0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"2026012114205980000_ehf213365-bib-0111","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/CIRCULATIONAHA.113.002203","article-title":"An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential","volume":"128","author":"Jay","year":"2013","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0112","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics"},{"key":"2026012114205980000_ehf213365-bib-0113","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005006.pub3","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"3","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012114205980000_ehf213365-bib-0114","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/CIRCULATIONAHA.111.021774","article-title":"Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms","volume":"124","author":"Scott","year":"2011","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1152\/japplphysiol.00148.2005","article-title":"Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity","volume":"100","author":"Chicco","year":"2006","journal-title":"J Appl Physiol"},{"key":"2026012114205980000_ehf213365-bib-0116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/0284186X.2013.781673","article-title":"Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial","volume":"53","author":"Hornsby","year":"2014","journal-title":"Acta Oncol"},{"key":"2026012114205980000_ehf213365-bib-0117","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","article-title":"Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training","volume":"15","author":"Haykowsky","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026012114205980000_ehf213365-bib-0118","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"6","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012114205980000_ehf213365-bib-0119","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"2026012114205980000_ehf213365-bib-0120","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"key":"2026012114205980000_ehf213365-bib-0121","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0122","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"2026012114205980000_ehf213365-bib-0123","doi-asserted-by":"crossref","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am Heart J"},{"key":"2026012114205980000_ehf213365-bib-0124","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction","volume":"2","author":"Dess\u00ec","year":"2011","journal-title":"Exp Ther Med"},{"key":"2026012114205980000_ehf213365-bib-0125","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0126","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0127","first-page":"936","article-title":"Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer","volume":"35","author":"Liu","year":"2013","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2026012114205980000_ehf213365-bib-0128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012114205980000_ehf213365-bib-0129","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0130","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of \u03b2-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026012114205980000_ehf213365-bib-0131","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026012114205980000_ehf213365-bib-0132","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cardfail.2013.12.018","article-title":"Cancer therapy-induced left ventricular dysfunction: interventions and prognosis","volume":"20","author":"Thakur","year":"2014","journal-title":"J Card Fail"},{"key":"2026012114205980000_ehf213365-bib-0133","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J ClinOncol"},{"key":"2026012114205980000_ehf213365-bib-0134","volume-title":"Adriamycin (DOXOrubicinHCl) for Injection","author":"Food and Drug Administration (FDA)","year":"2012"},{"key":"2026012114205980000_ehf213365-bib-0135","volume-title":"HERCEPTIN (trastuzumab)","author":"Food and Drug Administration (FDA)","year":"2010"},{"key":"2026012114205980000_ehf213365-bib-0136","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0137","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"8","author":"Walker","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0138","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijrobp.2017.05.030","article-title":"Strain imaging detects dose-dependent segmental cardiac dysfunction in the acute phase after breast irradiation","volume":"99","author":"Lo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026012114205980000_ehf213365-bib-0139","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/echo.13693","article-title":"Early assessment of the left ventricular function by epirubicin-induced cardiotoxicity in postoperative breast cancer patients","volume":"34","author":"Luo","year":"2017","journal-title":"Echocardiography"},{"key":"2026012114205980000_ehf213365-bib-0140","first-page":"835","article-title":"Early detection of the cardiotoxicity induced by chemotherapy drug through two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T","volume":"39","author":"Wang","year":"2017","journal-title":"ZhonghuaZhong Liu ZaZhi"},{"key":"2026012114205980000_ehf213365-bib-0141","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.amjcard.2018.08.019","article-title":"Usefulness of global longitudinal strain for early identification of subclinical left ventricular dysfunction in patients with active cancer","volume":"122","author":"Laufer-Perl","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0142","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1186\/s12885-018-4935-z","article-title":"Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer","volume":"18","author":"ArciniegasCalle","year":"2018","journal-title":"BMC Cancer"},{"key":"2026012114205980000_ehf213365-bib-0143","first-page":"411","article-title":"Atrial function in patients with breast cancer after treatment with anthracyclines","volume":"107","author":"Yaylali","year":"2016","journal-title":"Arq Bras Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0144","first-page":"50","article-title":"Left ventricular regional wall motion abnormality is a strong predictor of cardiotoxicity in breast cancer patients undergoing chemotherapy","volume":"112","author":"Barros","year":"2019","journal-title":"Arq Bras Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/postgradmedj-2016-134286","article-title":"Alterations in the echocardiographic variables of the right ventricle in asymptomatic patients with breast cancer during anthracycline chemotherapy","volume":"93","author":"Abdar Esfahani","year":"2017","journal-title":"Postgrad Med J"},{"key":"2026012114205980000_ehf213365-bib-0146","first-page":"1032","article-title":"Evaluation of changes in right ventricular myocardial mechanical properties in breast cancer patients receiving pirarubicin using three-dimensional speckle tracking imaging","volume":"38","author":"Wang","year":"2018","journal-title":"Nan Fang Yi Ke Da XueXueBao"},{"key":"2026012114205980000_ehf213365-bib-0147","first-page":"1308","article-title":"Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer","volume":"41","author":"Choe","year":"2018","journal-title":"ClinCardiol"},{"key":"2026012114205980000_ehf213365-bib-0148","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/clc.22872","article-title":"Left atrial volume in patients with HER2-positive breast cancer: one step further to predict trastuzumab-related cardiotoxicity","volume":"41","author":"Bergamini","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0149","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2019.06.030","article-title":"Myocardial tissue characterization and fibrosis by imaging","volume":"13","author":"Karamitsos","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114205980000_ehf213365-bib-0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/1354750X.2015.1040839","article-title":"New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide","volume":"2","author":"van Boxtel","year":"2015","journal-title":"Biomarkers"},{"key":"2026012114205980000_ehf213365-bib-0151","first-page":"1937","article-title":"Role of biomarkers in cardio-oncology","volume":"49","author":"Cardinale","year":"2011","journal-title":"ClinChem Lab Med"},{"key":"2026012114205980000_ehf213365-bib-0152","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clinbiochem.2014.10.013","article-title":"Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity","volume":"48","author":"Christenson","year":"2015","journal-title":"Clin Biochem"},{"key":"2026012114205980000_ehf213365-bib-0153","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0154","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2459\/JCM.0000000000000379","article-title":"Role of biomarkers in monitoring antiblastic cardiotoxicity. Special issue on cardiotoxicity from antiblastic drugs and cardioprotection","volume":"17","author":"Novo","year":"2016","journal-title":"J Cardiovasc Med"},{"key":"2026012114205980000_ehf213365-bib-0155","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00277-003-0615-3","article-title":"Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies","volume":"82","author":"Auner","year":"2003","journal-title":"Ann Hematol"},{"key":"2026012114205980000_ehf213365-bib-0156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096736","article-title":"BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography","volume":"9","author":"Skovgaard","year":"2014","journal-title":"PLoS One"},{"key":"2026012114205980000_ehf213365-bib-0157","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.3892\/ol.2016.4424","article-title":"Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity","volume":"11","author":"Wang","year":"2016","journal-title":"Oncol Lett"},{"key":"2026012114205980000_ehf213365-bib-0158","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0002-8703(98)70054-7","article-title":"Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease","volume":"135","author":"Stein","year":"1998","journal-title":"Am Heart J"},{"key":"2026012114205980000_ehf213365-bib-0159","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1373\/clinchem.2005.050153","article-title":"N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?","volume":"51","author":"Sandri","year":"2005","journal-title":"Clin Chem"},{"key":"2026012114205980000_ehf213365-bib-0160","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0161","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","article-title":"Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab","volume":"61","author":"Putt","year":"2015","journal-title":"Clin Chem"},{"key":"2026012114205980000_ehf213365-bib-0162","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0163","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018143","article-title":"Cardiotoxicity and cardiovascular biomarkers in patients with breast cancer: data from the GeparOcto-GBG 84 trial","volume":"9","author":"R\u00fcger","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012114205980000_ehf213365-bib-0164","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.clinbiochem.2013.03.014","article-title":"NT-proANP and NT-proBNP as prognostic markers in patients with acute decompensated heart failure of different etiologies","volume":"46","author":"Luers","year":"2013","journal-title":"Clin Biochem"},{"key":"2026012114205980000_ehf213365-bib-0165","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ijcard.2013.01.005","article-title":"Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF\/NT-proBNP risk score","volume":"168","author":"Scrutinio","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0166","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/01926230500519816","article-title":"Serum chemical biomarkers of cardiac injury for nonclinical safety testing","volume":"34","author":"Walker","year":"2006","journal-title":"Toxicol Pathol"},{"key":"2026012114205980000_ehf213365-bib-0167","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.bbadis.2012.12.014","article-title":"Biomarkers and diagnostics in heart failure","volume":"1832","author":"Gaggin","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2026012114205980000_ehf213365-bib-0168","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114205980000_ehf213365-bib-0169","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1158\/1078-0432.CCR-10-1359","article-title":"Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib","volume":"17","author":"Morris","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026012114205980000_ehf213365-bib-0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10549-012-2039-z","article-title":"High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study","volume":"134","author":"Onitilo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2026012114205980000_ehf213365-bib-0171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835919864236","article-title":"Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08\u201310 trial","volume":"11","author":"Gullo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"2026012114205980000_ehf213365-bib-0172","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00280-015-2874-9","article-title":"Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients","volume":"76","author":"Bulten","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026012114205980000_ehf213365-bib-0173","first-page":"708","article-title":"Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia","volume":"114","author":"Horacek","year":"2013","journal-title":"Bratisl Lek Listy"},{"key":"2026012114205980000_ehf213365-bib-0174","first-page":"97","article-title":"The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia","volume":"32","author":"Horacek","year":"2010","journal-title":"Exp Oncol"},{"key":"2026012114205980000_ehf213365-bib-0175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12185-008-0112-5","article-title":"Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation","volume":"88","author":"Zver","year":"2008","journal-title":"Int J Hematol"},{"key":"2026012114205980000_ehf213365-bib-0176","doi-asserted-by":"crossref","first-page":"6994","DOI":"10.18632\/oncotarget.14355","article-title":"Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"8","author":"Rigaud","year":"2017","journal-title":"Oncotarget"},{"key":"2026012114205980000_ehf213365-bib-0177","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3233\/CBM-181301","article-title":"Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin\/cyclophosphamide followed by docetaxel in patients with breast cancer","volume":"23","author":"Qin","year":"2018","journal-title":"Cancer Biomark"},{"key":"2026012114205980000_ehf213365-bib-0178","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.leukres.2015.08.009","article-title":"The impact of standard chemotherapy on miRNA signature in plasma in AML patients","volume":"39","author":"Koutova","year":"2015","journal-title":"Leuk Res"},{"key":"2026012114205980000_ehf213365-bib-0179","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/cvr\/cvq148","article-title":"Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway","volume":"87","author":"Horie","year":"2010","journal-title":"Cardiovasc Res"},{"key":"2026012114205980000_ehf213365-bib-0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10741-017-9653-0","article-title":"Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients","volume":"23","author":"Ruggeri","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2026012114205980000_ehf213365-bib-0181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2018.11.042","article-title":"Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity","volume":"110","author":"Gioffr\u00e9","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2026012114205980000_ehf213365-bib-0182","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/HCO.0000000000000050","article-title":"Macro advances in microRNAs and myocardial regeneration","volume":"29","author":"Wang","year":"2014","journal-title":"Curr Opin Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0183","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/CIRCRESAHA.112.269035","article-title":"MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes","volume":"110","author":"Jayawardena","year":"2012","journal-title":"Circ Res"},{"key":"2026012114205980000_ehf213365-bib-0184","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature09783","article-title":"Pervasive roles of microRNAs in cardiovascular biology","volume":"469","author":"Small","year":"2011","journal-title":"Nature"},{"key":"2026012114205980000_ehf213365-bib-0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2014.10.006","article-title":"Early biomarkers of doxorubicin-induced heart injury in a mouse model","volume":"281","author":"Desai","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026012114205980000_ehf213365-bib-0186","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/jhg.2013.42","article-title":"Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity","volume":"58","author":"Hertz","year":"2013","journal-title":"J Hum Genet"},{"key":"2026012114205980000_ehf213365-bib-0187","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J ClinOncol"},{"key":"2026012114205980000_ehf213365-bib-0188","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1389200218666171101124931","article-title":"Pharmacogenetics of metabolic genes of anthracyclines in acute myeloid leukemia","volume":"19","author":"Megias-Vericat","year":"2018","journal-title":"Curr Drug Metab"},{"key":"2026012114205980000_ehf213365-bib-0189","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2174\/0929867325666180327092639","article-title":"ABC transporters in extrahepatic tissues: pharmacological regulation in heart and intestine","volume":"26","author":"Villanueva","year":"2019","journal-title":"Curr Med Chem"},{"key":"2026012114205980000_ehf213365-bib-0190","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2011.11.022","article-title":"Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study","volume":"124","author":"Tian","year":"2012","journal-title":"Gynecol Oncol"},{"key":"2026012114205980000_ehf213365-bib-0191","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Canadian pharmacogenomics network for drug safety consortium pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J ClinOncol"},{"key":"2026012114205980000_ehf213365-bib-0192","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"CPNDS consortium validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2026012114205980000_ehf213365-bib-0193","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-015-3437-9","article-title":"Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients","volume":"152","author":"Vulsteke","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2026012114205980000_ehf213365-bib-0194","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide","volume":"102","author":"Bray","year":"2010","journal-title":"Br J Cancer"},{"key":"2026012114205980000_ehf213365-bib-0195","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/10428194.2016.1231405","article-title":"Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia","volume":"58","author":"Meg\u00edas-Vericat","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2026012114205980000_ehf213365-bib-0196","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0197","first-page":"38","article-title":"American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association","volume":"133","author":"Writing Group Members","year":"2016","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0198","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s13058-014-0446-2","article-title":"Risk determination and prevention of breast cancer","volume":"16","author":"Howell","year":"2014","journal-title":"Breast Cancer Res"},{"key":"2026012114205980000_ehf213365-bib-0199","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC Cardio Oncol"},{"key":"2026012114205980000_ehf213365-bib-0200","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0201","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114205980000_ehf213365-bib-0202","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1200\/JCO.2015.65.6603","article-title":"Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer","volume":"34","author":"Jones","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0203","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2007.15.9822","article-title":"Influence of pre-and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study","volume":"26","author":"Irwin","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026012114205980000_ehf213365-bib-0204","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"2026012114205980000_ehf213365-bib-0205","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13365","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13365","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/2397\/65568661\/eschf_8_4_2397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/2397\/65568661\/eschf_8_4_2397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:25:51Z","timestamp":1769023551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/4\/2397\/8344290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":205,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13365","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"2021-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}